de Loor H - Search Results

1

p-Cresol and cardiovascular risk in mild-to-moderate kidney disease.

Meijers BK, Claes K, Bammens B, de Loor H, Viaene L, Verbeke K, Kuypers D, Vanrenterghem Y, Evenepoel P. Meijers BK, et al. Among authors: de loor h. Clin J Am Soc Nephrol. 2010 Jul;5(7):1182-9. doi: 10.2215/CJN.07971109. Epub 2010 Apr 29. Clin J Am Soc Nephrol. 2010. PMID: 20430946 Free PMC article.

2

Gas chromatographic-mass spectrometric analysis for measurement of p-cresol and its conjugated metabolites in uremic and normal serum.

de Loor H, Bammens B, Evenepoel P, De Preter V, Verbeke K. de Loor H, et al. Among authors: de preter v. Clin Chem. 2005 Aug;51(8):1535-8. doi: 10.1373/clinchem.2005.050781. Clin Chem. 2005. PMID: 16040852 Free article. No abstract available.

3

p-Cresol for better or worse: but what are we measuring?

Meijers BK, de Loor H, Verbeke K, Evenepoel P. Meijers BK, et al. Among authors: de loor h. Kidney Int. 2006 Jul;70(1):232; author reply 232-3. doi: 10.1038/sj.ki.5001530. Kidney Int. 2006. PMID: 16810293 Free article. No abstract available.

4

The impact of renal allograft function on exposure and elimination of mycophenolic acid (MPA) and its metabolite MPA 7-O-glucuronide.

Naesens M, de Loor H, Vanrenterghem Y, Kuypers DR. Naesens M, et al. Among authors: de loor h. Transplantation. 2007 Aug 15;84(3):362-73. doi: 10.1097/01.tp.0000276936.14041.6c. Transplantation. 2007. PMID: 17700162 Clinical Trial.

5

Stability of mycophenolic acid and glucuronide metabolites in human plasma and the impact of deproteinization methodology.

de Loor H, Naesens M, Verbeke K, Vanrenterghem Y, Kuypers DR. de Loor H, et al. Clin Chim Acta. 2008 Mar;389(1-2):87-92. doi: 10.1016/j.cca.2007.11.033. Epub 2007 Dec 7. Clin Chim Acta. 2008. PMID: 18157945

6

Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients.

Kuypers DR, de Jonge H, Naesens M, de Loor H, Halewijck E, Dekens M, Vanrenterghem Y. Kuypers DR, et al. Among authors: de jonge h, de loor h. Clin Ther. 2008 Apr;30(4):673-83. doi: 10.1016/j.clinthera.2008.04.014. Clin Ther. 2008. PMID: 18498916 Clinical Trial.

7

Does the biomarker 15N-lactose ureide allow to estimate the site of fermentation of resistant starch?

Cloetens L, De Preter V, De Loor H, Rutgeerts P, Verbeke K. Cloetens L, et al. Among authors: de preter v, de loor h. Eur J Nutr. 2008 Jun;47(4):217-23. doi: 10.1007/s00394-008-0716-9. Epub 2008 Jun 16. Eur J Nutr. 2008. PMID: 18560788 Clinical Trial.

8

Sodium octanoate to reverse indoxyl sulfate and p-cresyl sulfate albumin binding in uremic and normal serum during sample preparation followed by fluorescence liquid chromatography.

de Loor H, Meijers BK, Meyer TW, Bammens B, Verbeke K, Dehaen W, Evenepoel P. de Loor H, et al. J Chromatogr A. 2009 May 29;1216(22):4684-8. doi: 10.1016/j.chroma.2009.04.015. Epub 2009 Apr 14. J Chromatogr A. 2009. PMID: 19394619

9

p-Cresyl sulfate and indoxyl sulfate in hemodialysis patients.

Meijers BK, De Loor H, Bammens B, Verbeke K, Vanrenterghem Y, Evenepoel P. Meijers BK, et al. Among authors: de loor h. Clin J Am Soc Nephrol. 2009 Dec;4(12):1932-8. doi: 10.2215/CJN.02940509. Epub 2009 Oct 15. Clin J Am Soc Nephrol. 2009. PMID: 19833905 Free PMC article.

10

Apparent elevation of cyclosporine whole blood concentrations in a renal allograft recipient.

de Jonge H, Geerts I, Declercq P, de Loor H, Claes K, Desmet K, Kuypers DR. de Jonge H, et al. Among authors: de loor h. Ther Drug Monit. 2010 Oct;32(5):529-31. doi: 10.1097/FTD.0b013e3181eb8442. Ther Drug Monit. 2010. PMID: 20625351

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

61 results

Search Page

Filters